<VariationArchive VariationID="6201" VariationName="NM_003560.4(PLA2G6):c.2370_2371del (p.Tyr790_Glu791delinsTer)" VariationType="Deletion" Accession="VCV000006201" Version="20" RecordType="classified" NumberOfSubmissions="10" NumberOfSubmitters="9" DateLastUpdated="2024-06-23" DateCreated="2014-11-23" MostRecentSubmission="2024-05-01">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="21240" VariationID="6201">
      <GeneList>
        <Gene Symbol="PLA2G6" FullName="phospholipase A2 group VI" GeneID="8398" HGNC_ID="HGNC:9039" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>22q13.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" start="38111495" stop="38181830" display_start="38111495" display_stop="38181830" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" start="38507501" stop="38577835" display_start="38507501" display_stop="38577835" Strand="-" />
          </Location>
          <OMIM>603604</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_003560.4(PLA2G6):c.2370_2371del (p.Tyr790_Glu791delinsTer)</Name>
      <CanonicalSPDI>NC_000022.11:38112210:CA:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>22q13.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" start="38112211" stop="38112212" display_start="38112211" display_stop="38112212" variantLength="2" positionVCF="38112210" referenceAlleleVCF="TCA" alternateAlleleVCF="T" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" start="38508218" stop="38508219" display_start="38508218" display_stop="38508219" variantLength="2" positionVCF="38508217" referenceAlleleVCF="TCA" alternateAlleleVCF="T" />
      </Location>
      <OtherNameList>
        <Name>NM_003560.4(PLA2G6):c.2370_2371del</Name>
        <Name>p.Tyr790_Glu791delinsTer</Name>
      </OtherNameList>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000022.10" sequenceAccession="NC_000022" sequenceVersion="10" change="g.38508218_38508219del" Assembly="GRCh37">
            <Expression>NC_000022.10:g.38508218_38508219del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000022.11" sequenceAccession="NC_000022" sequenceVersion="11" change="g.38112211_38112212del" Assembly="GRCh38">
            <Expression>NC_000022.11:g.38112211_38112212del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007094.3" sequenceAccession="NG_007094" sequenceVersion="3" change="g.107567_107568del">
            <Expression>NG_007094.3:g.107567_107568del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_033059.2" sequenceAccession="NG_033059" sequenceVersion="2" change="g.3458_3459del">
            <Expression>NG_033059.2:g.3458_3459del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001004426.3" sequenceAccession="NM_001004426" sequenceVersion="3" change="c.2208_2209del">
            <Expression>NM_001004426.3:c.2208_2209del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001004426.1" sequenceAccession="NP_001004426" sequenceVersion="1" change="p.Tyr736_Glu737delinsTer">
            <Expression>NP_001004426.1:p.Tyr736_Glu737delinsTer</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001587" Type="nonsense" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001199562.3" sequenceAccession="NM_001199562" sequenceVersion="3" change="c.2208_2209del">
            <Expression>NM_001199562.3:c.2208_2209del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001186491.1" sequenceAccession="NP_001186491" sequenceVersion="1" change="p.Tyr736_Glu737delinsTer">
            <Expression>NP_001186491.1:p.Tyr736_Glu737delinsTer</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001587" Type="nonsense" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001349864.2" sequenceAccession="NM_001349864" sequenceVersion="2" change="c.2370_2371del">
            <Expression>NM_001349864.2:c.2370_2371del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001336793.1" sequenceAccession="NP_001336793" sequenceVersion="1" change="p.Tyr790_Glu791delinsTer">
            <Expression>NP_001336793.1:p.Tyr790_Glu791delinsTer</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001587" Type="nonsense" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001349865.2" sequenceAccession="NM_001349865" sequenceVersion="2" change="c.2208_2209del">
            <Expression>NM_001349865.2:c.2208_2209del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001336794.1" sequenceAccession="NP_001336794" sequenceVersion="1" change="p.Tyr736_Glu737delinsTer">
            <Expression>NP_001336794.1:p.Tyr736_Glu737delinsTer</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001587" Type="nonsense" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001349866.2" sequenceAccession="NM_001349866" sequenceVersion="2" change="c.2208_2209del">
            <Expression>NM_001349866.2:c.2208_2209del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001336795.1" sequenceAccession="NP_001336795" sequenceVersion="1" change="p.Tyr736_Glu737delinsTer">
            <Expression>NP_001336795.1:p.Tyr736_Glu737delinsTer</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001587" Type="nonsense" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001349867.2" sequenceAccession="NM_001349867" sequenceVersion="2" change="c.1836_1837del">
            <Expression>NM_001349867.2:c.1836_1837del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001336796.1" sequenceAccession="NP_001336796" sequenceVersion="1" change="p.Tyr612_Glu613delinsTer">
            <Expression>NP_001336796.1:p.Tyr612_Glu613delinsTer</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001587" Type="nonsense" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001349868.2" sequenceAccession="NM_001349868" sequenceVersion="2" change="c.1692_1693del">
            <Expression>NM_001349868.2:c.1692_1693del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001336797.1" sequenceAccession="NP_001336797" sequenceVersion="1" change="p.Tyr564_Glu565delinsTer">
            <Expression>NP_001336797.1:p.Tyr564_Glu565delinsTer</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001587" Type="nonsense" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001349869.2" sequenceAccession="NM_001349869" sequenceVersion="2" change="c.1674_1675del">
            <Expression>NM_001349869.2:c.1674_1675del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001336798.1" sequenceAccession="NP_001336798" sequenceVersion="1" change="p.Tyr558_Glu559delinsTer">
            <Expression>NP_001336798.1:p.Tyr558_Glu559delinsTer</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001587" Type="nonsense" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_003560.4" sequenceAccession="NM_003560" sequenceVersion="4" change="c.2370_2371del" MANESelect="true">
            <Expression>NM_003560.4:c.2370_2371del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_003551.2" sequenceAccession="NP_003551" sequenceVersion="2" change="p.Tyr790_Glu791delinsTer">
            <Expression>NP_003551.2:p.Tyr790_Glu791delinsTer</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001587" Type="nonsense" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_1015" sequenceAccession="LRG_1015">
            <Expression>LRG_1015:g.107567_107568del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_1015t1" sequenceAccession="LRG_1015t1">
            <Expression>LRG_1015t1:c.2370_2371del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_1015p1" sequenceAccession="LRG_1015p1" change="p.Tyr790_Glu791delinsTer">
            <Expression>LRG_1015p1:p.Tyr790_Glu791delinsTer</Expression>
          </ProteinExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA173267" DB="ClinGen" />
        <XRef Type="Allelic variant" ID="603604.0007" DB="OMIM" />
        <XRef Type="rs" ID="587784353" DB="dbSNP" />
      </XRefList>
      <FunctionalConsequence Value="protein truncation">
        <XRef ID="0015" DB="Variation Ontology" />
      </FunctionalConsequence>
      <AlleleFrequencyList>
        <AlleleFrequency Value="0.00003" Source="The Genome Aggregation Database (gnomAD)" />
        <AlleleFrequency Value="0.00003" Source="The Genome Aggregation Database (gnomAD), exomes" />
        <AlleleFrequency Value="0.00004" Source="Exome Aggregation Consortium (ExAC)" />
        <AlleleFrequency Value="0.00005" Source="Trans-Omics for Precision Medicine (TOPMed)" />
      </AlleleFrequencyList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_003560.4(PLA2G6):c.2370_2371del (p.Tyr790_Glu791delinsTer) AND Infantile neuroaxonal dystrophy" Accession="RCV000006578" Version="18">
        <ClassifiedConditionList TraitSetID="1718">
          <ClassifiedCondition DB="MedGen" ID="C0270724">Infantile neuroaxonal dystrophy</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2024-01-29" SubmissionCount="4">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_003560.4(PLA2G6):c.2370_2371del (p.Tyr790_Glu791delinsTer) AND Neurodegeneration with brain iron accumulation 2B" Accession="RCV000006579" Version="7">
        <ClassifiedConditionList TraitSetID="1719">
          <ClassifiedCondition DB="MedGen" ID="C1857747">Neurodegeneration with brain iron accumulation 2B</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2008-10-28" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_003560.4(PLA2G6):c.2370_2371del (p.Tyr790_Glu791delinsTer) AND not provided" Accession="RCV000255768" Version="5">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-01-11" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_003560.4(PLA2G6):c.2370_2371del (p.Tyr790_Glu791delinsTer) AND Iron accumulation in brain" Accession="RCV000147322" Version="6">
        <ClassifiedConditionList TraitSetID="20141">
          <ClassifiedCondition DB="MedGen" ID="C4021076">Iron accumulation in brain</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2013-02-08" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_003560.4(PLA2G6):c.2370_2371del (p.Tyr790_Glu791delinsTer) AND Inborn genetic diseases" Accession="RCV002512837" Version="2">
        <ClassifiedConditionList TraitSetID="25797">
          <ClassifiedCondition DB="MedGen" ID="C0950123">Inborn genetic diseases</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-01-07" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_003560.4(PLA2G6):c.2370_2371del (p.Tyr790_Glu791delinsTer) AND PLA2G6-associated neurodegeneration" Accession="RCV002512838" Version="3">
        <ClassifiedConditionList TraitSetID="33682">
          <ClassifiedCondition DB="MedGen" ID="CN204472">PLA2G6-associated neurodegeneration</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-01-24" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_003560.4(PLA2G6):c.2370_2371del (p.Tyr790_Glu791delinsTer) AND multiple conditions" Accession="RCV002504755" Version="1">
        <ClassifiedConditionList TraitSetID="10340">
          <ClassifiedCondition DB="MedGen" ID="C2751842">Autosomal recessive Parkinson disease 14</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0270724">Infantile neuroaxonal dystrophy</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1857747">Neurodegeneration with brain iron accumulation 2B</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-09-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-01-29" NumberOfSubmissions="10" NumberOfSubmitters="9" DateCreated="2014-11-23" MostRecentSubmission="2024-05-01">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">16783378</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">18799783</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20619503</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20886109</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">27378808</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29915382</ID>
        </Citation>
        <DescriptionHistory Dated="2023-02-02">
          <Description>Pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="1719" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="5629" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">aNAD</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">atypical Neuroaxonal Dystrophy (aNAD)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">NEUROAXONAL DYSTROPHY, ATYPICAL</ElementValue>
                <XRef Type="MIM" ID="610217" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">NEURODEGENERATION WITH BRAIN IRON ACCUMULATION, PLA2G6-RELATED</ElementValue>
                <XRef Type="MIM" ID="610217" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Neurodegeneration with brain iron accumulation 2B</ElementValue>
                <XRef ID="MONDO:0012444" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">NBIA2B</ElementValue>
                <XRef Type="MIM" ID="610217" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">PLA2G6-associated neurodegeneration (PLAN) comprises a continuum of three phenotypes with overlapping clinical and radiologic features: Infantile neuroaxonal dystrophy (INAD). Atypical neuroaxonal dystrophy (atypical NAD). PLA2G6-related dystonia-parkinsonism. INAD usually begins between ages six months and three years with psychomotor regression or delay, hypotonia, and progressive spastic tetraparesis. Many affected children never learn to walk or lose the ability shortly after attaining it. Strabismus, nystagmus, and optic atrophy are common. Disease progression is rapid, resulting in severe spasticity, progressive cognitive decline, and visual impairment. Many affected children do not survive beyond their first decade. Atypical NAD shows more phenotypic variability than INAD. In general, onset is in early childhood but can be as late as the end of the second decade. The presenting signs may be gait instability, ataxia, or speech delay and autistic features, which are sometimes the only evidence of disease for a year or more. Strabismus, nystagmus, and optic atrophy are common. Neuropsychiatric disturbances including impulsivity, poor attention span, hyperactivity, and emotional lability are also common. The course is fairly stable during early childhood and resembles static encephalopathy but is followed by neurologic deterioration between ages seven and 12 years. PLA2G6-related dystonia-parkinsonism has a variable age of onset, but most individuals present in early adulthood with gait disturbance or neuropsychiatric changes. Affected individuals consistently develop dystonia and parkinsonism (which may be accompanied by rapid cognitive decline) in their late teens to early twenties. Dystonia is most common in the hands and feet but may be more generalized. The most common features of parkinsonism in these individuals are bradykinesia, resting tremor, rigidity, and postural instability.</Attribute>
                <XRef ID="NBK1675" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10688" />
                <XRef ID="10688" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301718</ID>
                <ID Source="BookShelf">NBK1675</ID>
              </Citation>
              <XRef ID="35069" DB="Orphanet" />
              <XRef ID="C1857747" DB="MedGen" />
              <XRef ID="MONDO:0012444" DB="MONDO" />
              <XRef Type="MIM" ID="610217" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="1718" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5628" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A</ElementValue>
                <XRef Type="MIM" ID="256600" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0001" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0007" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0003" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0006" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0014" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0015" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0004" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Infantile neuroaxonal dystrophy 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Seitelberger disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Infantile neuroaxonal dystrophy</ElementValue>
                <XRef ID="Neuroaxonal+dystrophy%2C+infantile/5159" DB="Genetic Alliance" />
                <XRef ID="52713000" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">INAD</ElementValue>
                <XRef Type="MIM" ID="256600" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">INAD1</ElementValue>
                <XRef Type="MIM" ID="256600" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">NBIA2A</ElementValue>
                <XRef Type="MIM" ID="256600" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">PLA2G6-Associated Neurodegeneration</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">PLA2G6-associated neurodegeneration (PLAN) comprises a continuum of three phenotypes with overlapping clinical and radiologic features: Infantile neuroaxonal dystrophy (INAD). Atypical neuroaxonal dystrophy (atypical NAD). PLA2G6-related dystonia-parkinsonism. INAD usually begins between ages six months and three years with psychomotor regression or delay, hypotonia, and progressive spastic tetraparesis. Many affected children never learn to walk or lose the ability shortly after attaining it. Strabismus, nystagmus, and optic atrophy are common. Disease progression is rapid, resulting in severe spasticity, progressive cognitive decline, and visual impairment. Many affected children do not survive beyond their first decade. Atypical NAD shows more phenotypic variability than INAD. In general, onset is in early childhood but can be as late as the end of the second decade. The presenting signs may be gait instability, ataxia, or speech delay and autistic features, which are sometimes the only evidence of disease for a year or more. Strabismus, nystagmus, and optic atrophy are common. Neuropsychiatric disturbances including impulsivity, poor attention span, hyperactivity, and emotional lability are also common. The course is fairly stable during early childhood and resembles static encephalopathy but is followed by neurologic deterioration between ages seven and 12 years. PLA2G6-related dystonia-parkinsonism has a variable age of onset, but most individuals present in early adulthood with gait disturbance or neuropsychiatric changes. Affected individuals consistently develop dystonia and parkinsonism (which may be accompanied by rapid cognitive decline) in their late teens to early twenties. Dystonia is most common in the hands and feet but may be more generalized. The most common features of parkinsonism in these individuals are bradykinesia, resting tremor, rigidity, and postural instability.</Attribute>
                <XRef ID="NBK1675" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3957" />
                <XRef ID="3957" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301718</ID>
                <ID Source="BookShelf">NBK1675</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">23447832</ID>
                <ID Source="BookShelf">NBK121988</ID>
              </Citation>
              <XRef ID="35069" DB="Orphanet" />
              <XRef ID="C0270724" DB="MedGen" />
              <XRef ID="MONDO:0024457" DB="MONDO" />
              <XRef Type="MIM" ID="256600" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="10340" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6750" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Autosomal recessive Parkinson disease 14</ElementValue>
                <XRef ID="MONDO:0013060" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Parkinson disease 14</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">DYSTONIA-PARKINSONISM, ADULT-ONSET</ElementValue>
                <XRef Type="MIM" ID="612953" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">PARK14</ElementValue>
                <XRef Type="MIM" ID="612953" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="12568" />
                <XRef ID="12568" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301402</ID>
                <ID Source="BookShelf">NBK1223</ID>
              </Citation>
              <Citation Type="general" Abbrev="EFNS/MDS-ES, 2013">
                <ID Source="PubMed">23279440</ID>
              </Citation>
              <XRef ID="199351" DB="Orphanet" />
              <XRef ID="C2751842" DB="MedGen" />
              <XRef ID="MONDO:0013060" DB="MONDO" />
              <XRef Type="MIM" ID="612953" DB="OMIM" />
            </Trait>
            <Trait ID="5628" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A</ElementValue>
                <XRef Type="MIM" ID="256600" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0001" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0007" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0003" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0006" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0014" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0015" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0004" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Infantile neuroaxonal dystrophy 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Seitelberger disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Infantile neuroaxonal dystrophy</ElementValue>
                <XRef ID="Neuroaxonal+dystrophy%2C+infantile/5159" DB="Genetic Alliance" />
                <XRef ID="52713000" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">INAD</ElementValue>
                <XRef Type="MIM" ID="256600" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">INAD1</ElementValue>
                <XRef Type="MIM" ID="256600" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">NBIA2A</ElementValue>
                <XRef Type="MIM" ID="256600" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">PLA2G6-Associated Neurodegeneration</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">PLA2G6-associated neurodegeneration (PLAN) comprises a continuum of three phenotypes with overlapping clinical and radiologic features: Infantile neuroaxonal dystrophy (INAD). Atypical neuroaxonal dystrophy (atypical NAD). PLA2G6-related dystonia-parkinsonism. INAD usually begins between ages six months and three years with psychomotor regression or delay, hypotonia, and progressive spastic tetraparesis. Many affected children never learn to walk or lose the ability shortly after attaining it. Strabismus, nystagmus, and optic atrophy are common. Disease progression is rapid, resulting in severe spasticity, progressive cognitive decline, and visual impairment. Many affected children do not survive beyond their first decade. Atypical NAD shows more phenotypic variability than INAD. In general, onset is in early childhood but can be as late as the end of the second decade. The presenting signs may be gait instability, ataxia, or speech delay and autistic features, which are sometimes the only evidence of disease for a year or more. Strabismus, nystagmus, and optic atrophy are common. Neuropsychiatric disturbances including impulsivity, poor attention span, hyperactivity, and emotional lability are also common. The course is fairly stable during early childhood and resembles static encephalopathy but is followed by neurologic deterioration between ages seven and 12 years. PLA2G6-related dystonia-parkinsonism has a variable age of onset, but most individuals present in early adulthood with gait disturbance or neuropsychiatric changes. Affected individuals consistently develop dystonia and parkinsonism (which may be accompanied by rapid cognitive decline) in their late teens to early twenties. Dystonia is most common in the hands and feet but may be more generalized. The most common features of parkinsonism in these individuals are bradykinesia, resting tremor, rigidity, and postural instability.</Attribute>
                <XRef ID="NBK1675" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3957" />
                <XRef ID="3957" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301718</ID>
                <ID Source="BookShelf">NBK1675</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">23447832</ID>
                <ID Source="BookShelf">NBK121988</ID>
              </Citation>
              <XRef ID="35069" DB="Orphanet" />
              <XRef ID="C0270724" DB="MedGen" />
              <XRef ID="MONDO:0024457" DB="MONDO" />
              <XRef Type="MIM" ID="256600" DB="OMIM" />
            </Trait>
            <Trait ID="5629" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">aNAD</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">atypical Neuroaxonal Dystrophy (aNAD)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">NEUROAXONAL DYSTROPHY, ATYPICAL</ElementValue>
                <XRef Type="MIM" ID="610217" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">NEURODEGENERATION WITH BRAIN IRON ACCUMULATION, PLA2G6-RELATED</ElementValue>
                <XRef Type="MIM" ID="610217" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Neurodegeneration with brain iron accumulation 2B</ElementValue>
                <XRef ID="MONDO:0012444" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">NBIA2B</ElementValue>
                <XRef Type="MIM" ID="610217" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">PLA2G6-associated neurodegeneration (PLAN) comprises a continuum of three phenotypes with overlapping clinical and radiologic features: Infantile neuroaxonal dystrophy (INAD). Atypical neuroaxonal dystrophy (atypical NAD). PLA2G6-related dystonia-parkinsonism. INAD usually begins between ages six months and three years with psychomotor regression or delay, hypotonia, and progressive spastic tetraparesis. Many affected children never learn to walk or lose the ability shortly after attaining it. Strabismus, nystagmus, and optic atrophy are common. Disease progression is rapid, resulting in severe spasticity, progressive cognitive decline, and visual impairment. Many affected children do not survive beyond their first decade. Atypical NAD shows more phenotypic variability than INAD. In general, onset is in early childhood but can be as late as the end of the second decade. The presenting signs may be gait instability, ataxia, or speech delay and autistic features, which are sometimes the only evidence of disease for a year or more. Strabismus, nystagmus, and optic atrophy are common. Neuropsychiatric disturbances including impulsivity, poor attention span, hyperactivity, and emotional lability are also common. The course is fairly stable during early childhood and resembles static encephalopathy but is followed by neurologic deterioration between ages seven and 12 years. PLA2G6-related dystonia-parkinsonism has a variable age of onset, but most individuals present in early adulthood with gait disturbance or neuropsychiatric changes. Affected individuals consistently develop dystonia and parkinsonism (which may be accompanied by rapid cognitive decline) in their late teens to early twenties. Dystonia is most common in the hands and feet but may be more generalized. The most common features of parkinsonism in these individuals are bradykinesia, resting tremor, rigidity, and postural instability.</Attribute>
                <XRef ID="NBK1675" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10688" />
                <XRef ID="10688" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301718</ID>
                <ID Source="BookShelf">NBK1675</ID>
              </Citation>
              <XRef ID="35069" DB="Orphanet" />
              <XRef ID="C1857747" DB="MedGen" />
              <XRef ID="MONDO:0012444" DB="MONDO" />
              <XRef Type="MIM" ID="610217" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="33682" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="18389" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">phospholipase A2-associated neurodegeneration</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">PLA2G6-associated neurodegeneration</ElementValue>
                <XRef ID="MONDO:0017998" DB="MONDO" />
                <XRef ID="329303" DB="Orphanet" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PLAN</ElementValue>
                <XRef Type="MIM" ID="256600" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">PLA2G6-associated neurodegeneration (PLAN) comprises a continuum of three phenotypes with overlapping clinical and radiologic features: Infantile neuroaxonal dystrophy (INAD). Atypical neuroaxonal dystrophy (atypical NAD). PLA2G6-related dystonia-parkinsonism. INAD usually begins between ages six months and three years with psychomotor regression or delay, hypotonia, and progressive spastic tetraparesis. Many affected children never learn to walk or lose the ability shortly after attaining it. Strabismus, nystagmus, and optic atrophy are common. Disease progression is rapid, resulting in severe spasticity, progressive cognitive decline, and visual impairment. Many affected children do not survive beyond their first decade. Atypical NAD shows more phenotypic variability than INAD. In general, onset is in early childhood but can be as late as the end of the second decade. The presenting signs may be gait instability, ataxia, or speech delay and autistic features, which are sometimes the only evidence of disease for a year or more. Strabismus, nystagmus, and optic atrophy are common. Neuropsychiatric disturbances including impulsivity, poor attention span, hyperactivity, and emotional lability are also common. The course is fairly stable during early childhood and resembles static encephalopathy but is followed by neurologic deterioration between ages seven and 12 years. PLA2G6-related dystonia-parkinsonism has a variable age of onset, but most individuals present in early adulthood with gait disturbance or neuropsychiatric changes. Affected individuals consistently develop dystonia and parkinsonism (which may be accompanied by rapid cognitive decline) in their late teens to early twenties. Dystonia is most common in the hands and feet but may be more generalized. The most common features of parkinsonism in these individuals are bradykinesia, resting tremor, rigidity, and postural instability.</Attribute>
                <XRef ID="NBK1675" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="12567" />
                <XRef ID="12567" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301718</ID>
                <ID Source="BookShelf">NBK1675</ID>
              </Citation>
              <XRef ID="329303" DB="Orphanet" />
              <XRef ID="CN204472" DB="MedGen" />
              <XRef ID="MONDO:0017998" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="25797" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="32761" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Inborn genetic diseases</ElementValue>
              </Name>
              <Citation Type="general" Abbrev="Langer et al., 2012">
                <ID Source="PubMed">22947299</ID>
              </Citation>
              <Citation Type="general" Abbrev="SACHDNC, 2013">
                <ID Source="PubMed">23037933</ID>
              </Citation>
              <Citation Type="general" Abbrev="EASAC/FEAM, 2013">
                <ID Source="PubMed">23169492</ID>
              </Citation>
              <Citation Type="general" Abbrev="ESHG/P3G/HUGO/PHGF, 2015">
                <ID Source="PubMed">25626707</ID>
              </Citation>
              <Citation Type="general" Abbrev="Alpha-1 Foundation, 2014">
                <ID Source="PubMed">24121147</ID>
              </Citation>
              <Citation Type="general" Abbrev="NBSTRN, 2015">
                <ID Source="PubMed">24394680</ID>
              </Citation>
              <Citation Type="general" Abbrev="EUNENBS, 2014">
                <ID Source="PubMed">23652378</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2014">
                <ID Source="PubMed">23881473</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/ACOG/NSGC/PQF/SMFM, 2015">
                <ID Source="PubMed">25730230</ID>
              </Citation>
              <Citation Type="general" Abbrev="Skirton et al., 2014">
                <ID Source="PubMed">24022298</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23619275</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2019">
                <ID Source="PubMed">31022120</ID>
              </Citation>
              <XRef ID="C0950123" DB="MedGen" />
              <XRef ID="D030342" DB="MeSH" />
            </Trait>
          </TraitSet>
          <TraitSet ID="20141" Type="Finding" ContributesToAggregateClassification="true">
            <Trait ID="30555" Type="Finding">
              <Name>
                <ElementValue Type="Preferred">Iron accumulation in brain</ElementValue>
                <XRef ID="HP:0012675" DB="Human Phenotype Ontology" />
              </Name>
              <XRef ID="C4021076" DB="MedGen" />
              <XRef Type="primary" ID="HP:0012675" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="342531" SubmissionDate="2014-09-11" DateLastUpdated="2014-11-23" DateCreated="2014-11-23">
        <ClinVarSubmissionID localKey="NM_003560.2(PLA2G6):c.2370_2371del" />
        <ClinVarAccession Accession="SCV000194695" DateUpdated="2014-11-23" DateCreated="2014-11-23" Type="SCV" Version="1" SubmitterName="Genetic Services Laboratory, University of Chicago" OrgID="1238" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2013-02-08">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2007</Attribute>
          <Citation Type="general">
            <ID Source="PubMed">18414213</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PLA2G6" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="22" start="38508218" />
          </Location>
          <AttributeSet>
            <Attribute Type="HGVS">NM_003560.2:c.2370_2371del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Finding">
          <Trait Type="Finding">
            <Name>
              <ElementValue Type="Preferred">iron accumulation in brain</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="CN185285" Type="CUI" />
            <XRef DB="HP" ID="HP:0012675" />
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="26761" SubmissionDate="2017-07-19" DateLastUpdated="2018-12-15" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="603604.0007_NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A" title="PLA2G6, 2-BP DEL, 2370TG_NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A" />
        <ClinVarAccession Accession="SCV000026761" DateUpdated="2018-12-15" DateCreated="2013-04-04" Type="SCV" Version="5" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2008-10-28">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">Neurodegeneration with Brain Iron Accumulation 2A</Attribute>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">In a patient with infantile neuroaxonal dystrophy (NBIA2A; 256600), Gregory et al. (2008) identified a homozygous 2-bp deletion (2370delTG) in the PLA2G6 gene, which resulted in premature termination at codon 790 similar to the Y790X mutation (603604.0006).</Attribute>
              <Citation>
                <ID Source="PubMed">18799783</ID>
              </Citation>
              <XRef DB="OMIM" ID="256600" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Neurodegeneration with Brain Iron Accumulation 2B</Attribute>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">In a patient with neurodegeneration with brain iron accumulation-2B (NBIA2B; 610217), Gregory et al. (2008) identified compound heterozygosity for the 2370delTG mutation and a 238G-A transition, resulting in an ala80-to-thr (A80T; 603604.0007) substitution. The patient presented at 3 years of age with toe walking and lower extremity spasticity. She developed optic atrophy and became nonambulatory by 5 years of age with dystonia and dysarthria, progressing to profound sensorimotor impairment by age 9 years. She died at age 23 years. Postmortem examination showed neuronal loss, axonal swelling, and Lewy bodies and neurofibrillary tangles.</Attribute>
              <Citation>
                <ID Source="PubMed">18799783</ID>
              </Citation>
              <XRef DB="OMIM" ID="610217" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PLA2G6" />
          </GeneList>
          <Name>PLA2G6, 2-BP DEL, 2370TG</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">2-BP DEL, 2370TG</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="603604.0007" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="26762" SubmissionDate="2017-07-19" DateLastUpdated="2018-12-15" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="603604.0007_NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2B" title="PLA2G6, 2-BP DEL, 2370TG_NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2B" />
        <ClinVarAccession Accession="SCV000026762" DateUpdated="2018-12-15" DateCreated="2013-04-04" Type="SCV" Version="5" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2008-10-28">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to included disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">Neurodegeneration with Brain Iron Accumulation 2A</Attribute>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">In a patient with infantile neuroaxonal dystrophy (NBIA2A; 256600), Gregory et al. (2008) identified a homozygous 2-bp deletion (2370delTG) in the PLA2G6 gene, which resulted in premature termination at codon 790 similar to the Y790X mutation (603604.0006).</Attribute>
              <Citation>
                <ID Source="PubMed">18799783</ID>
              </Citation>
              <XRef DB="OMIM" ID="256600" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Neurodegeneration with Brain Iron Accumulation 2B</Attribute>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">In a patient with neurodegeneration with brain iron accumulation-2B (NBIA2B; 610217), Gregory et al. (2008) identified compound heterozygosity for the 2370delTG mutation and a 238G-A transition, resulting in an ala80-to-thr (A80T; 603604.0007) substitution. The patient presented at 3 years of age with toe walking and lower extremity spasticity. She developed optic atrophy and became nonambulatory by 5 years of age with dystonia and dysarthria, progressing to profound sensorimotor impairment by age 9 years. She died at age 23 years. Postmortem examination showed neuronal loss, axonal swelling, and Lewy bodies and neurofibrillary tangles.</Attribute>
              <Citation>
                <ID Source="PubMed">18799783</ID>
              </Citation>
              <XRef DB="OMIM" ID="610217" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PLA2G6" />
          </GeneList>
          <Name>PLA2G6, 2-BP DEL, 2370TG</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">2-BP DEL, 2370TG</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="603604.0007" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="included">NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2B</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="6450634" SubmissionDate="2023-01-27" DateLastUpdated="2023-02-07" DateCreated="2023-02-07">
        <ClinVarSubmissionID localKey="f8f9030f-20ca-4a95-8331-0b234dc16ff2" localKeyIsSubmitted="1" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV003761456" DateUpdated="2023-02-07" DateCreated="2023-02-07" Type="SCV" Version="1" SubmitterName="Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard" OrgID="506627" OrganizationCategory="laboratory" OrgAbbreviation="Broad RDG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-01-24">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">20886109</ID>
          </Citation>
          <Comment>The c.2370_2371delTG variant in PLA2G6 has been reported in at least 5 individuals with PLA2G6-associated neurodegeneration (PMID: 18799783, 20619503, 29915382, 16783378), and has been identified in 0.007% (1/15202) of African/African American chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP ID: rs587784353). Although this variant has been seen in the general population in a heterozygous state, its frequency is low enough to be consistent with a recessive carrier frequency. This variant has also been reported in ClinVar (Variation ID#: 6201) and has been interpreted as pathogenic by Genetic Services Laboratory (University of Chicago), GeneDx, Baylor Genetics, Invitae, Centogene AG - the Rare Disease Company, and OMIM. Of the 5 affected individuals, 1 of those was a homozygote, and 3 were compound heterozygotes that carried reported likely pathogenic variants in trans or with unknown phase, which increases the likelihood that the c.2370_2371delTG variant is pathogenic (PMID: 18799783, 20619503, 29915382; ClinVar ID: 929943). In vitro functional studies provide some evidence that the p.Tyr790Ter variant may slightly impact protein function (PMID: 20886109). However, these types of assays may not accurately represent biological function. This variant is predicted to cause a frameshift, which alters the protein‚Äôs amino acid sequence beginning at position 790 and leads to a premature termination codon at the same position. This termination codon occurs within the last exon and is more likely to escape nonsense mediated decay (NMD) and result in a truncated protein. Loss of function of the PLA2G6 gene is an established disease mechanism in autosomal recessive PLA2G6-associated neurodegeneration. In summary, although additional studies are required to fully establish its clinical significance, this variant is likely pathogenic for autosomal recessive PLA2G6-associated neurodegeneration. ACMG/AMP Criteria applied: PVS1_moderate, PM2_supporting, PM3_strong, PS3_supporting (Richards 2015).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PLA2G6" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>NM_003560.4(PLA2G6):c.2370_2371del</Name>
            <Name>p.Tyr790_Glu791delinsTer</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000022.11:g.38112211_38112212del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0017998" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12627697</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="6243010" SubmissionDate="2024-04-20" DateLastUpdated="2024-05-01" DateCreated="2023-02-07">
        <ClinVarSubmissionID localKey="a9843029|MedGen:C0950123" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003551608" DateUpdated="2024-05-01" DateCreated="2023-02-07" Type="SCV" Version="2" SubmitterName="Ambry Genetics" OrgID="61756" OrganizationCategory="laboratory" OrgAbbreviation="Ambry" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-01-07">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">16783378</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18799783</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20619503</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20886109</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29915382</ID>
          </Citation>
          <Comment>The c.2370_2371delTG (p.Y790*) alteration, located in exon 17 (coding exon 16) of the PLA2G6 gene, consists of a deletion of 2 nucleotides from position 2370 to 2371. This changes the amino acid from a tyrosine (Y) to a stop codon at amino acid position 790. This alteration occurs at the 3' terminus of the PLA2G6 gene, is not expected to trigger nonsense-mediated mRNA decay, and only impacts the last 17/806 (2%) of the protein. However, premature stop codons are typically deleterious in nature and the impacted region is critical for protein function. Based on data from the Genome Aggregation Database (gnomAD) database, the PLA2G6 c.2370_2371delTG alteration was observed in 0.0033% (8/242472) of total alleles studied. The p.Y790* alteration has been reported in the homozygous and compound heterozygous state in multiple patients with PLA2G6-associated neurodegenerative disorders (Morgan, 2006; Gregory, 2008; Pais&amp;aacute;n-Ruiz, 2012; Sun, 2019). Functional studies demonstrate that the p.Y790* alteration has less than 10% catalytic activity in two substrates compared to wild type (Engel, 2010). Based on the available evidence, this alteration is classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Ambry Variant Classification Scheme 2023</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/i9igeqse/ambry_variant_classification_scheme_2023.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PLA2G6" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_003560.2:c.2370_2371delTG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0950123" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>AVA4 Submission_Through01042023</SubmissionName>
          <SubmissionName>FinalClinVarSubmissionFile_20140101to20240315_ava4_2</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2292879" SubmissionDate="2019-09-27" DateLastUpdated="2020-02-29" DateCreated="2020-02-29">
        <ClinVarSubmissionID localKey="NC_000022.10:g.38508218_38508219delCA|OMIM:256600" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001163822" DateUpdated="2020-02-29" DateCreated="2020-02-29" Type="SCV" Version="1" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" OrgAbbreviation="BCM: BMGL" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PLA2G6" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000022.10:g.38508218_38508219delCA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="256600" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>BG_GA_2018_SNVs_INDELS</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4033157" SubmissionDate="2021-12-21" DateLastUpdated="2022-01-14" DateCreated="2022-01-14">
        <ClinVarSubmissionID localKey="NM_003560.3:c.2370_2371del|OMIM:256600" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002059521" DateUpdated="2022-01-14" DateCreated="2022-01-14" Type="SCV" Version="1" SubmitterName="Centogene AG  - the Rare Disease Company" OrgID="279559" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-01-28">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PLA2G6" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_003560.3:c.2370_2371del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="256600" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10812468</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5464731" SubmissionDate="2022-12-13" DateLastUpdated="2022-12-31" DateCreated="2022-12-31">
        <ClinVarSubmissionID localKey="NM_003560.4:c.2370_2371del|OMIM:256600;610217;612953" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002805731" DateUpdated="2022-12-31" DateCreated="2022-12-31" Type="SCV" Version="1" SubmitterName="Fulgent Genetics, Fulgent Genetics" OrgID="500105" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-09-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_003560.4:c.2370_2371del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="TraitChoice">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="256600" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="610217" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612953" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12390657</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="616580" SubmissionDate="2022-02-16" DateLastUpdated="2023-03-04" DateCreated="2016-10-09">
        <ClinVarSubmissionID localKey="GDXSV:221481" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV000321927" DateUpdated="2023-03-04" DateCreated="2016-10-09" Type="SCV" Version="9" SubmitterName="GeneDx" OrgID="26957" OrganizationCategory="laboratory" OrgAbbreviation="GDX" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-01-11">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>Nonsense variant in the C-terminus predicted to result in protein truncation, as the last 17 amino acids are lost, and other loss-of-function variants have been reported downstream in the Human Gene Mutation Database (HGMD); Not observed at a significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 16783378, 18799783, 29915382)</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">GeneDx Variant Classification Process June 2021</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/fc81e176/genedx_variant_classification_process_june_2021.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PLA2G6" />
          </GeneList>
          <VariantType>Deletion</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">GDX:48393</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_003560.2:c.2370_2371del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not Provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GeneDX_Clinvar_Submission_88_20220216054204</SubmissionName>
          <SubmissionName>SUB5098196</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2746650" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2020-07-16">
        <ClinVarSubmissionID localKey="826380|MedGen:C0270724" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001411590" DateUpdated="2024-02-20" DateCreated="2020-07-16" Type="SCV" Version="5" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-01-29">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">16783378</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27378808</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29915382</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20886109</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Tyr790*) in the PLA2G6 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 17 amino acid(s) of the PLA2G6 protein. This variant is present in population databases (rs587784353, gnomAD 0.007%). This premature translational stop signal has been observed in individuals with clinical features of PLA2G6-related conditions (PMID: 16783378, 27378808, 29915382; Invitae). ClinVar contains an entry for this variant (Variation ID: 6201). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this premature translational stop signal affects PLA2G6 function (PMID: 20886109). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PLA2G6" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000022.10:g.38508218_38508219del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0270724" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200314</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="26761" TraitType="Disease" MappingType="Name" MappingValue="NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A" MappingRef="Preferred">
        <MedGen CUI="C0270724" Name="Infantile neuroaxonal dystrophy" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="6243010" TraitType="Disease" MappingType="XRef" MappingValue="C0950123" MappingRef="MedGen">
        <MedGen CUI="C0950123" Name="Inborn genetic diseases" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5464731" TraitType="Disease" MappingType="XRef" MappingValue="256600" MappingRef="OMIM">
        <MedGen CUI="C0270724" Name="Infantile neuroaxonal dystrophy" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2746650" TraitType="Disease" MappingType="XRef" MappingValue="C0270724" MappingRef="MedGen">
        <MedGen CUI="C0270724" Name="Infantile neuroaxonal dystrophy" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5464731" TraitType="Disease" MappingType="XRef" MappingValue="610217" MappingRef="OMIM">
        <MedGen CUI="C1857747" Name="Neurodegeneration with brain iron accumulation 2B" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="342531" TraitType="Finding" MappingType="Name" MappingValue="iron accumulation in brain" MappingRef="Preferred">
        <MedGen CUI="C4021076" Name="Iron accumulation in brain" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2292879" TraitType="Disease" MappingType="XRef" MappingValue="256600" MappingRef="OMIM">
        <MedGen CUI="C0270724" Name="Infantile neuroaxonal dystrophy" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="616580" TraitType="Disease" MappingType="Name" MappingValue="Not Provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="6450634" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0017998" MappingRef="MONDO">
        <MedGen CUI="CN204472" Name="PLA2G6-associated neurodegeneration" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5464731" TraitType="Disease" MappingType="XRef" MappingValue="612953" MappingRef="OMIM">
        <MedGen CUI="C2751842" Name="Autosomal recessive Parkinson disease 14" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="26762" TraitType="Disease" MappingType="Name" MappingValue="NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2B" MappingRef="Alternate">
        <MedGen CUI="C1857747" Name="Neurodegeneration with brain iron accumulation 2B" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4033157" TraitType="Disease" MappingType="XRef" MappingValue="256600" MappingRef="OMIM">
        <MedGen CUI="C0270724" Name="Infantile neuroaxonal dystrophy" />
      </TraitMapping>
    </TraitMappingList>
    <DeletedSCVList>
      <SCV>
        <Accession Version="1" DateDeleted="2019-04-05">SCV000853084</Accession>
        <Description>not specified</Description>
      </SCV>
    </DeletedSCVList>
  </ClassifiedRecord>
</VariationArchive>

